Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Masoudi-Khoram N et al. | 2022 | intact cell/cell culture, MCF-7 and MDA-MB-231 (human breast cancer cell lines) | magnetic field, low frequency, 50/60 Hz | - |
Loberg LI et al. | 2000 | intact cell/cell culture, MCF-7, ZR-75-1, T-47D, and MDA-MB-231 (breast cancer cell line) and normal human breast epithalial cells | magnetic field, 50/60 Hz | 1 mT |
Elexpuru-Zabaleta M et al. | 2023 | intact cell/cell culture, MDA-MB-231 and MCF-7 (breast cancer cell lines) and MCF-10A (breast cell line) | magnetic field, 50/60 Hz | - |
Lazzarini R et al. | 2023 | intact cell/cell culture, MDA-MB-231 cells (breast cancer cell line) and MDA-MB-231 (human breast cell line) | magnetic field, 50/60 Hz | - |
Shibaki R et al. | 2022 | intact cell/cell culture, MES-SA and MES-SA/DxS cells (human uterine sarcoma cell lines) | magnetic field, 50/60 Hz, co-exposure, also other exposures without EMF | - |
Miyakoshi J et al. | 2000 | intact cell/cell culture, MO54 cells (derived from a human malignant glioma) | magnetic field, 50/60 Hz, co-exposure | 5–400 mT |
Miyakoshi J et al. | 1997 | intact cell/cell culture, MeWo cells (malignant melanoma cells) | magnetic field, 50/60 Hz, also other exposures without EMF | 400–500 mT |
Calcabrini C et al. | 2017 | intact cell/cell culture, NCTC 2544 cells (human keratinocytes) | magnetic field, 50/60 Hz | 0.025–0.2 mT |
Soydas T et al. | 2024 | intact cell/cell culture, NIH/3T3 aged mouse fibroblasts | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | - |
Jia HL et al. | 2014 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | magnetic field, 50/60 Hz, co-exposure | 400 µT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.